Patient enrollment advancing in SERENITY At-Home Phase 3 trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or ...

In a report released today, David Amsellem from Piper Sandler maintained a Buy rating on Amneal Pharmaceuticals (AMRX – Research Report), with ...

NORTHFIELD, Minn., Feb. 4, 2025 /PRNewswire/ -- Aurora Pharmaceutical, a leader in animal health solutions, is proud to announce a 30% expansion of its sales force over the past three years.

Perform material- and labor-effective extrusion with Thermo Scientific™ Pharma 11 Twin-screw Extruder, which requires only a small amount of active pharmaceutical ingredient, operating at ...

LabVantage Pharma is the only pre-configured and pre-validated pharmaceutical LIMS in the world. This greatly lowers the deployment cost (85%) and time (75%) compared to a traditional LIMS ...

The stock's fall snapped a two-day winning streak.

Shares of Biogen Inc. BIIB slid 1.10% to $142.34 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.76% to 5,994.57 and Dow ...

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other S&P 500 stocks. 2024 was a memorable year for the broad market index, which posted a gain ...

Fresh off a reorganization, Biogen’s research leader Jane Grogan says the biotech has to 'look outside the walls of the ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

Biogen (NASDAQ:BIIB) shares experienced a change in market expectations as Cantor Fitzgerald revised the company's price target. The new target has been set at $206.00, a decrease from the previous ...